BioMarin Pharmaceuticals
BMRN
306 hedge funds and large institutions have $9.95B invested in BioMarin Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 101 increasing their positions, 115 reducing their positions, and 39 closing their positions.
63% more call options, than puts
Call options by funds: $94.9M | Put options by funds: $58.2M
31% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 39
4% more funds holding
Funds holding: 294 → 306 (+12)
2% less capital invested
Capital invested by funds: $10.1B → $9.95B (-$167M)
12% less repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 115
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Top Buyers
| 1 |
Wells Fargo
San Francisco,
California
|
+$97.2M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$78.6M |
| 3 |
Alkeon Capital Management
New York
|
+$68M |
| 4 |
Millennium Management
New York
|
+$60.7M |
| 5 |
State Street
Boston,
Massachusetts
|
+$50M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$265M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$40.1M |
| 3 |
Goldman Sachs
New York
|
-$39.5M |
| 4 |
D.E. Shaw & Co
New York
|
-$38.4M |
| 5 |
ACPU
Arrowgrass Capital Partners (US)
Dover,
Delaware
|
-$34.4M |
BMRN Hedge Fund Activity: Q4 2013 in Review
306 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2013, worth a combined $9.95B — down 1.7% from $10.1B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new BMRN positions and 39 closed out — a net gain of 12 holders — while 101 added to existing stakes and 115 trimmed.
The largest buyer was Wells Fargo, adding an estimated $97.2M. The largest seller was Fidelity Investments, cutting an estimated $265M.
- 306 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2013, up from 294 in Q3 2013.
- Funds reported $9.95B of BioMarin Pharmaceuticals stock for Q4 2013, down 1.7% quarter-over-quarter.
- 51 funds opened new BioMarin Pharmaceuticals positions in Q4 2013 and 39 closed out, a net change of +12 holders.
- The largest BioMarin Pharmaceuticals buyer in Q4 2013 was Wells Fargo, an estimated $97.2M added.
- The largest BioMarin Pharmaceuticals seller in Q4 2013 was Fidelity Investments, an estimated $265M sold.
Based on aggregated 13F filings for Q4 2013.